A Phase 3 Trial of MM120 for Generalized Anxiety Disorder
Do you struggle with anxiety? You are not alone.
We are doing research for a new investigational treatment option to see if it is effective in improving anxiety. If you suffer from anxiety, you may be eligible to participate.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating MM120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment.
Initial Eligibility Criteria:
- 18 - 74 years old
- Experiencing Anxiety
- Willing to use a highly effective method of contraception
- Willing to stop all medication affecting your mood
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers
One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design. Depending on the study arm, participants will either receive an inactive placebo or up to 25mg psilocybin (oral dose), in one of two set and setting conditions; drug administration contexts that are predicted to modulate drug effects.
The purpose of this study is to evaluate any interaction effects between an oral dose of psilocybin and the surrounding context (set and setting).
